New assessment reveals value of second embryo biopsy for women of advanced maternal age

An elegant new study confirms that the most commonly used method of screening for embryo abnormalities following in vitro fertilization (IVF) does accurately predict the success of embryo transplantation for younger women, but not necessarily for those of advanced maternal age.

Currently, some IVF laboratories screen for chromosomal abnormalities by taking a biopsy of the trophectoderm (TE) cells, the cells that become the and umbilical cord, and assessing them with a DNA microarray. However, are susceptible to mosaicism, in which one group of cells develops differently from a neighboring group due to a spontaneous . This causes chromosomes to differ not only among TE cells but also between these nascent placental cells and inner cell mass (ICM) cells, which develop into the embryo itself.

To evaluate the chromosomal status in human blastocysts, researchers led by Dr. Wei-Hua Wang collected 244 blastocysts from women undergoing IVF, biopsied the TE cells, and assessed all 23 pairs of chromosomes.

The results revealed by microarray indicated that 56.6% of the 244 blastocysts had an abnormal number of chromosomes. Of those, 62.3% had single and 37.7% had multiple or complex . Consistent with earlier studies, blastocysts from patients aged 38 or older were found to be much more likely to have abnormal chromosome numbers (56.4.0%) than those from patients aged 37 or younger (43.9.2%). Further, a mere 18% of embryos from women aged 41 and older had the correct number of chromosomes and were deemed suitable for transplant.

When the blastocysts that passed the initial inspection were transplanted, they resulted in high (average 70.2%) independent of the age of the mother.

After this initial assessment, the team rebiopsied 13 of the abnormal blastocysts to compare the TE and ICM cells from the same embryos using two different array platforms. Nine of the 13 blastocysts were found to be mosaic (69.23%) and, of those, four had normal ICM cells that could potentially have produced healthy offspring. The authors therefore conclude that the commonly employed method of biopsy of TE cells alone does not predict chromosomal problems in ICM cells when there is an abnormal number of chromosomes and that older women should consider having their abnormal embryos rebiopsied if they need additional embryos for transplant.

There is clearly much left to discover in this field, and more information will be revealed as IVF clinics continue to use blastocyst microarray for embryo screening.

More information: Liu J, Wang W, Sun X, Liu L, Jin H, Li M, Witz C, Williams D, Griffith J, Skorupski J, Haddad G, Gill J. DNA microarray reveals that high proportions of human blastocysts from women of advanced maternal age are aneuploid and mosaic. Biol Reprod 2012; (in press). Published online ahead of print 7 November 2012; DOI 10.1095/biolreprod.112.103192

Provided by Society for the Study of Reproduction

not rated yet

Related Stories

First use of DNA fingerprinting to identify viable embryos

May 14, 2008

Fertility researchers have used DNA fingerprinting for the first time to identify which embryos have implanted after in vitro fertilisation (IVF) and developed successfully to result in the births of healthy babies. The technique, ...

First babies born from genetic screening study

Oct 15, 2010

Two women taking part in the world's first controlled study of a comprehensive genetic screening test before IVF have given birth to healthy babies. The babies, twin girls born in Germany in June and a singleton boy born ...

Recommended for you

Improving life before it begins

6 hours ago

A group of Mexican specialists in fetal medicine have successfully performed over 200 surgeries on unborn babies, inside the womb of the mother. Doctors, grouped under the signature Fetal Medicine Mexico, ...

Letrozole may help women with PCOS become pregnant

Jul 09, 2014

The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn State College ...

User comments